Home

Home

cells

ABOUT CELYAD ONCOLOGY

Celyad Oncology is a biotechnology company focused on the research and discovery of chimeric antigen receptor (CAR) T-cell therapies for cancer.

More Info About Celyad ONCOLOGY

Latest News

376_981be

Celyad announces management change

Publication of a transparency notification

Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology reports third quarter 2023 financial results and recent business highlights

Celyad Oncology published in Molecular Therapy – Nucleic Acids a manuscript detailing our proprietary microRNA (miRNA)-based multiplex shRNA platform

Celyad Oncology announces the termination of its American Depository Receipt program

Publication of a rectified transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)

Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
Discover All News

Our SCIENCE

At Celyad Oncology, we are pursuing next-generation cellular immunotherapies by applying our broad understanding of immunology, novel technology platforms and modular design approach to drug discovery.

Read More About Our SCIENCE

Novel CAR T-cell Immunotherapies

Advancing both allogeneic and autologous CAR T-cell therapy candidates for the treatment of cancer

View Pipeline
Artwork of lymphocytes.

Twitter feed is not available at the moment.

View All

Stay informed about the latest news!

Sign up FOR our newsletter

    By clicking on “send”, you consent that your personal data will be processed by us in order to send you our newsletter. You have the right to access, rectify, erase your data, to restrict the processing and the right to withdraw your consent at any time. You can find more information on how we process your data in our Privacy Policy.